Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced positive top-line data from a Phase Ia study of IW-1701, an investigational soluble ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News Management Comments

Mizuho Securities Reiterates Buy Following Ironwood Pharma's (IRWD) Strong 4Q Results February 19, 2016 9:30 AM BTIG Sees Opportunity in Ironwood Pharma (IRWD) Weakness; Affirms at 'Buy'February 19, 2016 7:50 AM Leerink Partners Remains Sidelined After Ironwood Pharma's (IRWD) 4Q February 19, 2016 7:22 AM Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701February 18, 2016 8:00 AM